Rhodanine Derivatives as Anticancer Agents: QSAR and Molecular Docking Studies. 2023

Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
Department of Applied Chemistry and Ecology, Faculty of Food Technology Osijek, Josip Juraj Strossmayer University of Osijek, F. Kuhača 18 31000 Osijek, Croatia.

Rhodanine derivatives have a proven wide range of biological activities. The aim of this study was to evaluate the cytotoxic effect of a series of rhodanine derivatives and investigate the quantitative structure-activity relationships, as well as binding modes to tyrosine kinase. Cytotoxic effect on cell proliferation (CaCo-2, HeLa, MDCK-1, Hut-78, K562) in vitro was evaluated by the MTT viability assay. QSAR analysis was performed with Dragon descriptors using QSARINS software. Molecular docking was performed on the tyrosin kinase (c-Src) (PDB ID: 3G6H) using iGEMDOCK. Compounds with the best inhibiting activity toward all cell lines were the ones possessing only one group in the C2 of the phenyl ring. QSAR study on the cytotoxic activity against Human T cell lymphoma achieved the model that satisfies the fitting and internal cross-validation criteria (R2 = 0.75; Q2 LOO = 0.64). Descriptors included in the model (MATS2e, MATs7e, RDF060p) revealed the importance of the presence of atoms with higher polarizability in the outer region of molecules. The findings of the molecular docking study performed on the c-Src are in accordance with the results of the QSAR study. The key interactions with binding site residues were achieved through oxygen atoms from phenoxy and rhodanine groups and rhodanine sulphur atoms. Rhodanine derivatives could be developed as novel tyrosine kinase inhibitors in the treatment of leukemia.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012236 Rhodanine
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D018938 Caco-2 Cells Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells, such as ENTEROCYTES. These cells are valuable in vitro tools for studies related to intestinal cell function and differentiation. Caco 2 Cells,Caco-2 Cell,Cell, Caco-2,Cells, Caco-2
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
January 2022, Journal of oncology,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
April 2017, European journal of medicinal chemistry,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
August 2023, Chemical biology & drug design,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
January 2022, Anti-cancer agents in medicinal chemistry,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
October 2023, Journal of biomolecular structure & dynamics,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
May 2023, RSC advances,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
August 2021, Asian Pacific journal of cancer prevention : APJCP,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
November 2016, Bioorganic & medicinal chemistry,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
January 2021, Anti-cancer agents in medicinal chemistry,
Maja Molnar, and Melita Lončarić, and Teuta Opačak-Bernardi, and Ljubica Glavaš-Obrovac, and Vesna Rastija
September 2022, Molecules (Basel, Switzerland),
Copied contents to your clipboard!